Real-world data sources

Your patient’s characteristics used to select the most similar RWE source(s)		RWE sources selected were large international studies and registries French, German and Austrian studies were not included due to missing data			Key patient factors selected that were commonly reported across studies ECOG ≥2 and prior ASCT were not included in the calculation due to missing and/or very similar results
Patient profile	CIBMTR¹ View study	CAR T-Cell Consortium² View study	Italy³ View study	Spain⁴ View study	France⁵ View study	Germany⁶ View study	Austria⁷ View study
No. of patients infusedwith tisa-cel	682	92	99	129	209	183	31
Age, median (range)	66.5 (14–91)	67 (IQR 61–72)	53 (19–70)	61 (23–76)	64 (20–81)	61 (19–83)	61 (30–83)
ECOG ≥2	5%	7%	NR	8%	13%	16%	0%
High gradelymphoma	13%	7%	12%	16%	NR	NR	20%
Prior lines of therapy,median	3	4	3	2	2	NR73% ≥3 lines	NR55% ≥3 lines
Primary refractory	38%	20%	69%	56%	NR	NR	NR
Prior ASCT	26%	25%	30%	29%	22%	35%	33%

References: 1. Landsburg DJ et al. American Society of Hematology Annual Meeting, 11–14 December 2021, Atlanta, GA. Abstract 429.
2. Riedell PA et al. Transplant Cell Ther 2022;28(10):669–676.
3. Chiappella A et al. American Society of Hematology Annual Meeting, 11–14 December 2021, Atlanta, GA. Abstract 3867.
4. Kwon M et al. American Society of Hematology Annual Meeting, 11–14 December 2021, Atlanta, GA. Abstract 1742.
5. Bachy E et al. Nat Med. 2022;28(10):2145–2154.
6. Bethge WA et al. Blood. 2022;140(4):349–358.
7. Rudzki JD et al. American Society of Hematology Annual Meeting, 10–13 December 2022, New Orleans, LA. Poster 2964.

Your patient summary will be shown here as you save you patient selections

This is where your patient summary will be shown. If you would like more tailored data, create a patient profile

3L+ DLBCL PATIENT

Patient profile

Treatment history

Treatment choice